Directed Evolution of an Artificial Imine Reductase by Hestericová, Martina et al.





Directed Evolution of Artificial Imine Reductase 
Martina Hestericová[a], Tillman Heinisch[a], Lur Alonso-Cotchico[b], J.-D. Maréchal*[b], Pietro Vidossich[b], 
and Thomas R. Ward*[a] 
 
Abstract: Artificial metalloenzymes, resulting from incorporation 
of a metal cofactor within a host protein, have received increasing 
attention in the last decade. Herein, we report on the directed 
evolution of an Artificial Transfer Hydrogenase (ATHase) based 
on the biotin-streptavidin technology using a straightforward 
optimized protocol allowing screening in cell free extracts. Our 
efforts yielded two streptavidin isoforms with improved catalytic 
activity and selectivity for the reduction of cyclic imines. 
Gratifyingly, the evolved ATHases proved stable under biphasic 
catalytic conditions. The X-ray structure analysis reveals that 
introducing bulky residues within the active site results in flexibility 
changes of the cofactor, thus increasing exposure of the metal to 
the protein surface and leading to a reversal of enantioselectivity. 
This hypothesis was confirmed by a multiscale approach based 
mostly on molecular dynamics and protein-ligand dockings. 
Biocatalysis offers an attractive means to produce high-
added value products.[1] Its limitations in reaction repertoire, 
substrate scope and operational stability can be overcome using 
directed evolution or encapsulation techniques.[2] 
Chiral amines, representing important intermediates for 
synthesis of biologically active compounds, agrochemicals, 
flavors and fragrances, are gaining increasing importance in both 
academic and industrial sectors. Since approximately 40 % of all 
pharmaceuticals contain at least one chiral amine building 
block,[3] the demand for their selective synthesis is immense. 
Current strategies to produce enantioenriched amines include 
organic synthesis,[4] resolution of racemates[5] or biocatalysis.[6] 
Amine dehydrogenases,[7] phenylalanine ammonia lyases,[8] 
transaminases[9] or imine reductases[10] have been reported for 
chiral amine synthesis; monoamine oxidases[11] and lipases[12] for 
biocatalytic kinetic resolution of amines. Implementation of imine 
reductases in preparative biocatalysis remains a challenge, 
mainly because of the instability of the substrates in water, limited 
substrate acceptance, non-competitive price and a limited 
number of available enzymes.[10] 
In the past fifteen years, biocatalysis has been 
complemented with artificial metalloenzymes (ArMs). These 
combine attractive features of enzymatic catalysis with the vast  
 
Figure 1. Close-up view of the active site of an artificial imine reductase. The protein 
is displayed as solvent accessible surface and the biotinylated cofactor as color-coded 
stick. Positions selected for mutagenesis are highlighted (PDB code: 3PK2). 
reaction repertoire of organometallic catalysis.[13] In this context, 
the biotin-streptavidin technology[14] has proven versatile, 
allowing the development of numerous ArMs that have been 
optimized to catalyze new-to-nature transformations.[15] 
In order to fine-tune the performance of enzymes, directed 
evolution has proven extremely powerful.[16] Consisting of iterative 
cycles of (random) mutagenesis, protein overexpression and 
screening, this versatile technique allows to incrementally 
improve a targeted feature of an enzyme: activity, selectivity, 
stability etc. As ArMs consist of an abiotic cofactor and a 
genetically-encoded host protein, directed evolution can also be 
applied to the optimization of such hybrid catalysts.[17] 
In order to speed-up the directed evolution of artificial 
metalloenzymes based on the biotin-streptavidin technology, we 
set out to perform catalysis using E. coli cell free extracts (cfe 
hereafter) rather than purified protein samples. Previously, we 
identified glutathione as a main contaminant,[18] leading to the 
irreversible poisoning of the precious metal biotinylated cofactor 
when catalysis is performed in cfe. Addition of diamide (1,1-
azobis(N,N-dimethylformamide) to cfe containing streptavidin 
(Sav) prior to the addition of the cofactor restores to a large extent 
the catalytic performance of the ArMs.[18b] To test the usefulness 
of this straightforward screening protocol, we set out to optimize 
the performance of an artificial imine reductase based on the 
biotin-streptavidin technology by directed evolution. 
 In this work, we present the experimental implementation of 
a streamlined optimization protocol,[19] which allows us to screen 
hundreds of mutant protein variants using cfe pre-incubated with 
diamide. Upon screening only 300 variants contained in cfe, which 
corresponds to approx. four weeks of mutagenesis and 
expression, four weeks of protein purification, and 200 hours of 
analytical measurements, two mutants with an increased catalytic 
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activity and opposite selectivity for the reduction of cyclic imines 
were identified.  
In order to improve the catalytic performance of the artificial 
imine reductase, we selected an area of 10 Å around the iridium 
center of the biotinylated cofactor anchored within the streptavidin 
active site and subjected the corresponding amino acids to 
iterative saturation mutagenesis (Figure 1 and Supporting 
Information). As starting point for the screen, we used mature 
Sav[20] with mutation K121A. For the first generation of the 
directed evolution, a reduced library of amino acids was included. 
At positions T111, S112, G113, T114, A116, N118, S122, T123 
and L124, the following residues were introduced relying on 
precise primers: A, V, L, D, E, Q, K, H, M, Y, S, P (or N if one of 
the targeted mutation is present at this position). For the following 
generations, all canonical amino acids were individually 
introduced. Mutants were overexpressed in E. coli in 96 deep-well 
plates, and the cells were: i) lysed, ii) treated with diamide and 
incubated for 15 minutes, iii) supplemented with [Cp*Ir(biot-p-
L)Cl] and iv) screened for the transfer hydrogenation of three 
cyclic imines 1a, 1b and 1c (Scheme 1, See SI for full 
experimental details). After identification of improved variants 
using cfe, the corresponding mutants were overexpressed in 1 L 
autoinduction ZYP- 5052 medium[21] in shake flasks, purified by 
iminobiotin-sepharose affinity chromatography and lyophilized. 
The pure Sav mutants were then tested for their ATHase activity 
in the presence of [Cp*Ir(biot-p-L)Cl]. 
In the first generation, positions S112 and N118 were 
screened, yielding (S)- and (R)-selective mutants K121A-S112R 
and K121A-N118P, respectively (Table 1, entries 4 and 5; Figure 
2). Next, K121A-N118P was subjected to focused saturation 
mutagenesis in position S112. Mutant K121A-N118P-S112A 
yielded (R)-2a with an ee = 86 % (entry 6). Position S122 was 
mutated next. Substituting the polar serine to a methionine further 
improved the enantioselectivity for the reduction of 1a, yielding 
92 % ee (R)-2a and full conversion (entry 7). We hypothesized, 
that mutating alanine to bulky arginine at position 112 would afford 
the opposite enantiomer of 2a. To our delight, the resulting Sav 
variant produced (S)-2a in 63 % ee and with improved conversion 
(entry 9).  
Scheme 1. Reduction of cyclic imines 1a, 1b and 1c using ATHase based on 
the biotin-streptavidin technology. 
 
Figure 2. Summary of the directed evolution path to afford both an (R)- and an 
(S)-selective ATHase for the reduction of 1a. 
The (S)-selectivity was further improved by introducing bulky 
tyrosine instead of lysine at position 124, which for the reduction 
of 1a, yielded (S)-2a with an ee = 78 % ee and full conversion 
(entry 10). Because of the low solubility of 1a in water, we 
performed experiments under a biphasic set-up[22] with 100 mM 
substrate 1a dissolved in ethyl acetate. To our delight, improved 
enantioselectivity was observed for both (R)- and (S)-selective 
ATHases (entries 8 and 12). In stark contrast, [Cp*Ir(biot-p-L)Cl] 
· K121A proved less active and less selective under biphasic 
conditions (entry 3). Preparative scale experiments (>120 mg of 
substrate) resulted in >99 % GC yield (70 % isolated yield) and 
91 % ee for Sav S112A-N118P-K121A-S122M and >75 % GC 
yield (55 % isolated yield) and -71 % ee for Sav S112R-N118P-
K121A-S122M-L124Y, respectively (Table 1, entries 9 and 13). 
Table 1. Selected results for the reduction of cyclic imine 1a using purified 
proteins.[a]  






1 [Cp*Ir(biot-p-L)Cl] 0 17 35 
2 K121A 54 99 198 
3 K121A [b] 31 5 100 
4 N118P-K121A 59 96 193 
5 S112R-K121A -27 36 72 
6 S112A-N118P-K121A 86 100 200 
7 S112A-N118P-K121A-S122M 92 100 200 
8 S112A-N118P-K121A-S122M[b] 95 19 380 
9 S112R-N118P-K121A-S122M[c] 91 99 (70e) 198 
10 S112R-N118P-K121A-S122M -63 90 179 








-72 75 (55e) 150 
[a] The reactions were performed with 10 mM substrate at 37°C for 48 h (see SI 
for details). [b] Reactions were performed in a biphasic system with 100 mM 
substrate at RT for 4 days. [c] Preparative scale reaction, 124 mg of 1a were 
added to 60 ml of reaction mixture. [d] Enantiomeric excess and conversion were 
determined by means of HPLC analysis. Positive ee values correspond to (R)-
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Scheme 2. - Saturation kinetic data for selected ATHases based on 
incorporation of [Cp*Ir(biot-p-L)Cl] (2 eq.) in various Sav isoforms (1 eq.) for the 
reduction of imine 1a or 1b. Error bars represent ± standard deviation. 
The resulting Sav library was tested for the reduction of the 
bulky isoquinoline 1b as well as cyclic imine 1c (Table S3). For 
the reduction of 1b, an (S)-selective mutant following an evolution 
route bearing mutation N118K was identified: [Cp*Ir(biot-p-L)Cl] · 
S112T-N118K-K121A-S122K affords (S)-2b with an ee = 50% ee 
and 75 % conversion after 48 hours (Table S3 entry 8, Figure S4). 
The highest (S)-selectivity for the reduction of 1c was obtained 
with Sav S112R-N118P-K121A-S122M-L124Y, yielding (S)-2c in 
an ee = 55 % ee and 86 % conversion (Table S3, entry 22, Figure 
S4). 
Next, the saturation kinetic behavior of the bare cofactor as 
well as the best performing ATHases was determined (Scheme 2; 
Table S4). As can be appreciated from these data, mutant 
[Cp*Ir(biot-p-L)Cl] · Sav K121A displays an 8-fold increased kcat 
value for the reduction of 1b compared to the bare cofactor. 
Moreover, both mutants K121A-N118P-S112A-S122M and 
K121A-N118P-S112R-S122M-L124Y display improved reaction 
rates for the reduction of 1b compared to the bare cofactor. 
Introducing a bulky tyrosine residue at position 124 has a dramatic 
effect on KM, increasing its value to 50 mM from 7.4 mM for the 
bare cofactor. Both ATHase mutants S112R-N118P-K121A-
S122M-L124Y and S112A-N118P-K121A-S122M display very 
similar KM values, while their kcat differ significantly. This suggests 
that introducing a second bulky substituent at position 112 
contributes to stabilization of the reaction transition state, thus 
improving the reaction rate for the (S)-selective ATHase. 
Substrate inhibition is encountered for mutants K121A and 
S112R-N118P-K121A-S122M-L124Y, whereas the free cofactor 
and mutant S112A-N118P-K121A-S122M display classical 
Michaelis–Menten kinetics, even at high substrate concentrations. 
Unlike the results obtained from the reduction of 1b, addressing 
the kinetic behavior of ATHases for the reduction of 1a revealed 
that none of the tested mutants could reach substrate inhibition 
dues to limited solubility of 1a. Compared to the bare cofactor, all 
mutants display slightly higher kcat coupled with lower KM values. 
To gain structural insight into the best performing ATHases, 
crystals of S112R-N118P-K121A-S122M-L124Y and S112A-
N118P-K121A-S122M mutants were soaked with a solution 
containing an excess [Cp*Ir(biot-p-L)Cl]. Inspection of the X-ray 
structure of [Cp*Ir(biot-p-L)Cl] · S112A-N118P-K121A-S122M 
Sav (Figure 3a) highlights the structural similarities to the 
structure of [Cp*Ir(biot-p-L)Cl] · S112A Sav.[23] The overall 
ATHase structure and the position and absolute configuration of 
the piano stool moiety are virtually identical (RMSD of all Ca = 
0.693). Due to potential steric clashes between two symmetry-
related cofactors, the chloride ligand was not modeled. However, 
the crystal structure suggests the preferred formation of an (S)-
configuration at the metal for [Cp*Ir(biot-p-L)Cl] (i.e. (R)-
configuration for the catalytically active hydride [Cp*Ir(biot-p-L)H]) 
(Figure S6A). The piano stool localization within the biotin-binding 
vestibule is stabilized by an H-bond between the A121 backbone 
carbonyl oxygen and the amine nitrogen of the piano stool 
complex. As the cationic lysine residue at position K121 is 
substituted by an apolar alanine residue, it prevents a possible 
interaction with the imine nitrogen of the substrate. The non-
concerted transition state allowing CH⋅⋅⋅π interaction between the 
Cp* moiety and the phenyl of 1a allows for the formation of (R)-
2a. The X-ray structure of [Cp*Ir(biot-p-L)Cl] · S112R-N118P-
K121A-S122M-L124Y Sav (Figure 3B) reveals that introducing 
bulky residues S112R and L124Y within the Sav monomer-
monomer interface results in a nearly 180° rotation of the piano 
stool moiety around the Cbenzene-Ssulfonamide bond. The position of 
the pianostool is stabilized by an H-bond between the Y124 side 
chain hydroxyl and the amino group of the cofactor (Figure 
S7B,C). Unfortunately, no electron density was present to model 
the {Cp*IrCl} moiety. We speculate that is may be due to 
increased flexibility of the surface-exposed complex or partial 
dissociation of the {Cp*IrCl}. Increased cofactor exposure, 
presumably leads to increased solvent exposure of the substrate 
(Figure S7B). This is reminiscent to the structure of an ATHase 
[Cp*Ir(biot-p-L)Cl] · S112K Sav (PDB code 4OKA).[23] Importantly, 
both crystal structures of the evolved ATHases presented herein 
reveal increased atomic B-factors within the loop-7,8 and the 
surface-exposed terminus of the cofactor when compared to 
published ATHases S112A and S112K (PDB 3PK2 and 4OKA 
respectively) (Figure S10, Table S5).[18] In the latter structures, the 
loop-7,8 is conformationally rigidified by an H-bonding network 
including i) the N118 side chain amide, ii) a water molecule and 
iii) the T115 backbone amide. Mutation N118P results in 
elimination of this H-bonding network (Figure S11A). Additional 
flexibility is produced in loop 7,8 through mutation S122M that 
induces breaking of H-bonds in a Sav monomer-monomer 
interface (Figure S11B).  
 
 
Figure 3. Close-up view of the crystal structures of complexes [(Cp*)Ir(Biot-p-
L)Cl] · S112A-N118P-K121A-S122M Sav (PDB 6ESS) (A) and [(Cp*)Ir(Biot-p-
L)Cl] · S112R-N118P-K121A-S122M -L124Y Sav (PDB 6ESU) (B). The protein 
is displayed as transparent surface and cartoon model with mutations 
highlighted in red in stick model. Only one cofactor per Sav tetramer is displayed 
for clarity. The cofactor is contoured with electron density from a 2FoFc map in 
marine (1.0 s) and an anomalous dispersion density map in red (4.0 s). Magenta 
atoms are not resolved in the electron density. 





These observations are reminiscent of the elevated atomic B-
factors found in the crystal structure of a Sav-based 
metathase.[17f] 
Crystal structures were determined assuming saturation of 
Sav monomers by the cofactor. However, catalysis was 
performed under a 1:2 ratio of cofactor per Sav monomer. To 
structurally characterize the assemblies under catalytic conditions, 
Molecular Dynamics (MD) simulations were performed using an 
implicit solvent approach and applying metadynamics to initially 
boost the exploration of conformational space (see Supporting 
Information for further details). The achiral planar catalytic [Ir(III)] 
16e- two-legged pianostool was considered. Conformations from 
the MD trajectories were grouped (clustered) based on the 
cofactor position in the vestibule. The number of configurations in 
each group (cluster) is displayed in Figure S13a,b together with 
an estimate of the interaction energy between the [Ir] complex 
(excluding the biotin fragment) and the protein (Figure S13c,d). 
Variant S112R-N118P-K121A-S122M-L124Y was computed to 
bind the cofactor more tightly than variant S112A-N118P-K121A-
S122M. This observation may be explained based on the polarity 
of the residues in the vestibule, which is more hydrophobic for 
S112A-N118P-K121A-S122M. Accordingly, the MD trajectory of 
S112R-N118P-K121A-S122M-L124Y shows reduced mobility of 
the cofactor compared to S112A-N118P-K121A-S122M. The 
conformation of the cofactor in the most populated cluster in the 
trajectory of S112A-N118P-K121A-S122M is very similar to the X-
ray determination (Figure S14A). However, further conformations 
are accessible to the cofactor via rotation around the S–N bond 
(Figure S14B). Similarly, the conformation of the cofactor in the 
most populated cluster in the trajectory of S112R-N118P-K121A-
S122M-L124Y is consistent with the X-ray structure (See Figure 
S12C). 
Next, we used this structural insight to rationalize the 
opposite enantioselectivity resulting from [Cp*Ir(biot-p-L)Cl] · 
S112R-N118P-K121A-S122M-L124Y and [Cp*Ir(biot-p-L)Cl] · 
S112A-N118P-K121A-S122M variants towards substrate 1a. For 
this purpose, we docked the protonated form of 1a to the 
representative structures of selected clusters. The resulting 
structures were energy-minimized and the substrate binding 
energy estimated. We did not attempt to estimate reaction 
energies (i.e. with QM/MM methods).  
In the most populated cluster from the MD trajectory of 
S112R-N118P-K121A-S122M-L124Y Sav, [Cp*Ir(biot-p-L)H] 
leads to the formation of (R)-2a. The best docking solutions for 
the pro-R and pro-S faces of 1a project the phenyl substituent in 
a pocket formed by residues R112 and Y124 from both monomers 
and P118 of the adjacent monomer. The difference between the 
two binding poses consists in the orientation of the imine plane: 
the NH group points towards the hydroxyl of tyrosine Y124 in the 
pro-S structure (Figure 4a), whereas it is rotated by 180 degrees 
and does not display interactions in the pro-R structure (Figure 
4b). From a docking point of view, the pro-R binding mode is 
slightly favored over the pro-S one. However, MD simulations 
starting from these structures reveal that the pro-R binding mode 
is not stable, whereas the pro-S displays a longer lifetime (i.e. 
about 200 ps). During this time, the NH group reorients to form an 
H-bond to the backbone carbonyl of A121. Based on this data, we 
conclude that [Cp*Ir(biot-p-L)H] · S112R-N118P-K121A-S122M-
L124Y Sav should preferentially reduce the pro-S face of 1a, an 
observation in agreement with the experimental knowledge. 
 
 
Figure 4. Substrate 1a docked to the most populated cluster from MD 
simulations of Sav variants S112R-N118P-K121A-S122M-L124Y (panel a and 
b) and S112A-N118P-K121A-S122M (c). The cofactor is shown in blue stick, 
with the Cp* group in cyan and the Ir-H atoms as balls; the substrate is shown 
as sticks with the reactive C atom as a larger ball; the protein surface is shown 
in gray, with the residues within 4 Å colored by type: white for hydrophobic 
residues, green for polar, blue for positively charged.  
Concerning mutant S112A-N118P-K121A-S122M, docking 
of 1a to the representative structure of the most populated cluster 
(which would form the (R)-configuration of the metal-hydride) 
results in a binding mode with no clear preference for the 
reduction of either the pro-R or the pro-S faces of the substrate 
1a. In this binding mode, 1a sits on the hydrophobic surface 
formed by residues L110, A112, T114, P118, A121, L124 (Figure 
4c). We also considered binding of 1a to representative structures 
of other clusters. In all cases, binding turned to be weaker than 
for the most populated. The MD simulations started from these 
bound structures did not reveal any alternative long-lived binding 
mode. It seems then that the ee observed experimentally for this 
mutant cannot be easily rationalized from a pure binding process 
and further aspects including the calculation of reaction barriers 
may be required.  
In summary, introduction of a biotinylated iridium piano stool 
complex [Cp*Ir(Biot-p-L)Cl] within streptavidin isoforms affords 
artificial imine reductases. These can be optimized by directed 
evolution protocols using cell free extracts (i.e. unpurified 
samples), thus dramatically improving the throughput of the effort. 
Two mutants with increased reaction rates and 
enantioselectivities were identified for the reduction of cyclic imine 
1a, allowing for the formation of both (R)-2a (95 % ee) and (S)-2a 
(86 % ee) using the same cofactor. The possibility of performing 
catalysis in a biphasic medium and on preparative scale paves 
the way for greater scope of applications of such hybrid catalysts. 
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